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The aim of this study was to investigate the relationship between the effect of emergency treatment and 
inflammatory markers in patients with acute exacerbations of obstructive pulmonary disease, especially with 
respect to smoking history. We investigated 50 unselected patients with acute bronchial obstruction. Blood, urine 
and sputum samples were taken and analysed for eosinophil and neutrophil markers. The patients were observed 
for at least 2 h and recordings of forced expiratory volume in 1 s (FEV,) were taken. They were re-examined after 1 
and 4 weeks. The absolute levels of inflammatory markers did not differ significantly between non- or short-term 
smokers (5 5 pack-years) and long-term smokers (> 5 pack-years) with the exception of myeloperoxidase in serum 
(S-MPO), which was higher in long-term smokers. The patients with higher levels of eosinophil markers before 
emergency treatment experienced a greater improvement in lung function. In non- or short-term smokers this 
relationship was found in blood and urine, whereas in long-term smokers it was seen in sputum. No correlation was 
found between neutrophil markers and changes in lung function. We conclude that patients with obstructive 
pulmonary disease with acute exacerbations and high levels of eosinophil markers respond well to treatment. 
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Introduction 
Bronchial inflammation and obstruction are features 
common to both asthma and chronic obstructive pulmon- 
ary disease (COPD). It is well-known that eosinophil cells 
and their products play an important role in the pathogen- 
esis of asthma (1,2). In COPD, the neutrophil cell is 
considered to be more important (3-5), but some studies 
have also demonstrated increased levels of eosinophil 
markers in COPD (3,&g). During acute exacerbations, 
bronchial inflammation is increased (10). In one study, the 
total numbers of eosinophils had a predictive value among 
asthma patients (11). 
In the clinical situation, there may be considerable 
difficulty differentiating between asthma and COPD. This 
is particularly true of the acute phase of these diseases. Both 
asthma and COPD are common diseases and we must 
therefore accept the possibility that some patients will have 
an overlap of both diseases. As COPD in practice only 
develops in long-term smokers, questions relating to 
smoking history may provide some indication of whether 
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a patient with an acute exacerbation has asthma or COPD. 
Even in asthma, a long smoking history may indicate a 
poor prognosis. In a study by Pedersen et al. (12), smoking 
asthmatics did not respond to inhaled steroids. 
The aim of this study was to investigate the relationship 
between the effect of emergency treatment and inflamma- 
tory markers, in blood, urine and sputum, in a group of 
patients with obstructive lung disease with acute exacerba- 
tions. A further objective was to study whether this 
relationship differs according to smoking history. 
Material and methods 
SUBJECTS 
The subjects comprised adult patients (> 18 years) with 
acute exacerbations of obstructive lung disease, both 
asthma and COPD, presenting during the daytime at the 
emergency room in our department. They were all assessed 
as being in need of emergency treatment including steroids. 
The patients were free of oral steroids and their daily dose 
of inhaled steroids was a maximum of 1600 pg (800 pg, if 
fluticasone was used). They were excluded from the study, if 
hospital admission was deemed necessary or if they were 
unable to perform the lung function tests. Out of 50 
patients who participated in this study 45 were re-examined 
with complete protocol after 1 week and 43 after 4 weeks. 
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Participation was voluntary and the study was approved by 
the Ethics Committee at the Medical Faculty at Uppsala 
University. 
Before treatment, all patients were examined and 
spirometry (Vitalograph Alfa, Vitalograph Ltd., Bucking- 
ham, U.K.) was performed. This was repeated after 15, 30, 
60 and 120 min. The predicted value of FEVl was 
calculated for each patient (13). Blood samples were taken 
before treatment was given. The patients were asked to 
cough deeply and deliver a sputum sample. No induction 
with saline was used. The urine samples were taken during 
the first 30 min. 
THE TREATMENT 
All patients were given 5-l 5 mg of nebulized salbutamol (in 
one to three doses) via VentstreamTM with a Porta Neb 
compressor (Medic Aid Ltd., West Sussex, U.K.). The first 
28 patients were included as part of a multicentre study. 
They were treated after randomization with 8 mg of 
nebulized budesonide (2 x 4 mg), 60 mg of prednisolone 
p.o. or placebo treatment. At discharge and at bedtime on 
the first day, patients who had received nebulized budeso- 
nide or placebo in the acute phase received one dose of 
400 pg of budesonide via a dry powder inhaler (Turbo- 
halera Astra-Draco, Lund, Sweden) and the patients who 
had received prednisolone in the acute phase were given 
placebo Turbohale@). The next morning, prednisolone 
patients started with 30 mg of prednisolone daily for 1 week 
and the remaining patients continued with 400 pg of 
budesonide Turbohaler@ q.i.d. for one week. Up to this 
point, the study was strictly double-blind. After completing 
the multicentre study, a local study was conducted in 
Uppsala with a further 22 patients in whom the treatment 
was open and comprised 60 mg of prednisolone p.o. in the 
acute phase and 30 mg of prednisolone p.o. daily the 
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FIG. 1. The treatment in the different groups during the 
study period. 
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following week. Apart from the treatment, the same study 
protocol was followed as in the multicentre study. After 1 
week, all the patients continued with 800 pg of budesonide 
Turbohale? b.i.d. (Fig. 1). At the follow-up after 1 and 4 
weeks, further spirometry was performed. 
INFLAMMATORY MARKERS 
Eosinophil cationic protein (ECP) was measured using the 
Pharmacia CAP system @ ECP FEIA (Pharmacia & 
Upjohn Diagnostics AB, Uppsala, Sweden), according to 
the manufacturer’s instructions. The inter- and intra-assay 
variation was less than 8% and the detection limit less than 
2 pg 1-l. 
Eosinophil peroxidase (EPO) was assessed using a 
prototype immunofluorometric assay utilizing the Pharma- 
cia CAP system@. Briefly, EPO, purified, with some 
modifications, according to the previously described 
method (14), was used as a standard ranging from 0.5- 
200 ,ug 1-l. Monoclonal antibodies (MoAbs) were produced 
using the hybridoma technique. One MoAb was covalently 
bound to the immunoCAP@ and the other MoAb was 
labelled with the enzyme P-galactosidase. The assay 
procedures were identical to that of ECP. Cross-reactivity 
with ECP and myeloperoxidase (MPO) in the EPO assay 
was ~0.3 and co.01 % respectively. The detection limit for 
the EPO assay was 0.5 pg 1-I and the inter- and intra-assay 
coefficient of variation was less than 10%. 
Eosinophil protein X (EPX) was measured in urine using 
Pharmacia EPX RIA (Pharmacia & Upjohn Diagnostics 
AB, Uppsala, Sweden), according to the manufacturer’s 
instructions. Urine samples were diluted 11 times in a 
phosphate buffer, pH 7.4, containing 0.15 M NaCL, 1% 
BSA, 0.1% Tween 20, 10 mM EDTA and 0.2% CTAB. The 
inter- and intra-assay variation was less than 10% and the 
detection limit less than 3 pg-‘. The degree of dilution of 
urine in the kidneys was determined by measuring the 
concentration of creatinine using the alkaline picrate 
method (Jaffk’s reaction, HiCo creatinine, Boehringer 
Mannheim GmbH, Germany). The EPX results are 
expressed as micrograms of EPX per millimole of 
creatinine. 
lnterleukin-5 (IL-5) was analysed using the Quantikine 
human IL-5 enzyme immunoassay (R&D Systems 
Europe Ltd., Abingdon, U.K.), according to the manufac- 
turer’s instructions. The inter- and intra-assay variation 
was less than 10% and the detection limit less than 
7.8 pg 1-l. 
Myeloperoxidase (MPO) was measured using radio 
immunoasssays, according to the manufacturer’s instruc- 
tions (Pharmacia MPO RIA, Pharmacia & Upjohn 
Diagnostics AB, Uppsala, Sweden) and human neutrophil 
lipocaline (HNL), as previously described (15). Inter- and 
intra-assay variations were less than 10% and the detection 
limit less than 8 pug 1-l and 4 pg 1-l respectively. 
Total neutrophil and total eosinophil counts (B-neutro, 
B-eos) were measured using standard techniques at the 
hospital’s Department of Clinical Chemistry. 
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SERUM 
Serum was prepared by allowing venous blood to clot for 
60-120 minutes at 20°C followed by centrifugation at 1600g 
at 4°C for 10 min. The serum samples were kept at -70°C 
until analysis. 
SPUTUM 
Total content of inflammatory markers: Only sputum 
samples with visible sputum plugs were used. Sputum plugs 
were collected from the sample and frozen and thawed 
once. The sample was then diluted with an equal volume of 
phosphate buffered saline (PBS) and mixed for 30 s on a 
vortex mixer. Following ultrasonication at power setting 3 
for 10 s, the homogenized sample was diluted twice with 
(PBS), supplemented with 0.4% N-cetyltrimethyl ammo- 
nium bromide (CTAB), (PBS/CTAB), and incubated at 
room temperature for 60 min. After centrifugation at 
15 OOOg for 5 min, the supernatant was stored at -20°C 
until the analyses of ECP, EPO and IL-5 were performed, 
For measurements of IL-5 the addition of PBSjCTAB was 
omitted. 
URINE 
The urine samples, which were collected during the first 
30 min of the patient’s visit were then immediately frozen at 
- 70°C pending analysis. 
STATISTICAL METHODS 
The statistical analyses were performed with the StatView- 
SE+ graphics software from Abacus Concepts Inc, (Ber- 
kely, CA, U.S.A.) and StatView 5.0 from SAS Institute Inc. 
(Cary, NC, U.S.A.) Comparisons between patients and 
controls were performed using the Mann-Whitney U-test 
for continuous variables, while the chi-square test was used 
for comparisons of proportions. Correlations between 
continuous variables on an ordinal scale were performed 
using Spearman’s rank correlation test. Multivariate 
analysis was performed by multiple logistic regression. A 
P-value of 0.05 or less was regarded as statistically 
significant. 
Results 
ALL PATIENTS 
The mean age of the patients was 65 (range 22-88). There 
were 28 women (56%) and 22 men (44%). The mean FEVi 
(% pred) before treatment was 48% & 24 (mean * SD). The 
improvement (d) in FEVi (% of baseline) after 1 week was 
24% +41 and 31%+59 after 4 weeks. There was no 
significant difference in dFEVi between the different 
treatment groups. The mean number of pack-years was 
20 (range &76). Only six patients were current smokers, 
another four had stopped during the past year. All patients 
were on short-acting &agonists, 18 patients were on long- 
acting flz-agonists and 11 patients were on ipratropium- 
bromide. Eight patients did not have inhaled steroids before 
the study, the others had a daily dose of 400-1600 pg. 
Of the 50 patients who attended visit 1, one did not wish 
to come for the follow-up after 1 week and three patients 
did not wish to come after 4 weeks. Complete records were 
obtained from 45 patients at 1 week and from 43 patients at 
4 weeks. The drop-outs did not differ regarding age, sex, 
smoking history, lung function or inflammatory markers 
compared to the remaining patients. 
There was a significant correlation between the level of 
EPX in urine, sputum ECP and sputum EPO and the 
change in FEVi (d) after 2 h (Table 1). After 1 week, there 
TABLE 1. The correlation between eosinophil markers before treatment and the change in lung function 2 h, 1 and 4 weeks 
(r-values) 
dFEVi (% of baseline) 
After 2 h After 1 week After 4 weeks 
S-ECP O-16 0.20 0.36* 
S-EPO 0.02 0*44** 0.40* 
U-EPX/crea o-40** 0.24 0*37* 
B-eos o-09 0.38* 0.29 
Sputum IL-5 0.34 o-34 0.38 
Sputum ECP o-37* 0.46* 0*59** 
Sputum EPO 0*45* 0*68** 0.56** 
B-neutro -0.14 -0.04 0.10 
S-MPO 0.12 -0.15 0.06 
S-HNL 0.20 0.02 o-12 
*p<o*o5, **p<o*o1, ***P < 0.001. S-ECP: Serum eosinophil cationic protein; S-EPO: serum eosinophil peroxidase, U-EPX 
urinary eosinophil protein X; S-MPO: serum myeloperoxidase, S-HNL: serum human neutrophil lipocaline. 
was a significant correlation between AFEV, and S-EPO, 
sputum ECP and sputum EPO. After 4 weeks, a significant 
correlation was seen between AFEVi and S-ECP, S-EPO, 
EPX in urine, sputum ECP and sputum EPO. No significant 
correlation was seen between the neutrophil markers and A 
FEV, after 2 h or after 1 and 4 weeks (Table 1). 
Patients who experienced an improvement in FEVi of 
more than 20% of baseline after 1 and 4 weeks had higher 
levels of eosinophil markers before treatment than patients 
whose FEVi improved by 5 20%. This was significant at 
the l-week follow-up for S-EPO (52 +_44 vs. 25 +_ 30 pg l-l), 
sputum EPO (66594 vz. 4$_4 mg 1-l) (P<O.Ol), U-EPX 
(103+78 vs. 71+ 52 ,ug mmol-I), B-Eos (567f346 vs. 
362_+285 lo6 1-i) and sputum ECP (63_+94 vs. 14f21 mg 
1-l) (P<O.O5). Patients who experienced an improvement 
of more than 20% after 4 weeks of treatment had 
significantly higher pre-treatment levels of ECP and EPO 
in both serum and sputum (Fig. 2) and significantly higher 
levels of U-EPX (126 _+ 93 vs. 73 _+ 52 pg mmol-‘) (PC 0.05) 
and B-Eos (596f304 vs. 364k321 IO6 1-l) (P<O.O5). 
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FIG. 2. Pre-treatment levels of eosinophil cationic protein 
(ECP) and eosinophil peroxidase (EOP) in serum and 
sputum. The box plots show the values of median, the 
25th and 75th percentiles (box) and the 10th (I) and the 
90th (T). a) patients with AFEVi 520% of baseline after 
4 weeks. b) patients with AFEVi >20% of baseline after 4 
weeks. 
INFLAMMATORY MARKERS IN OBSTRUCTIVE PULMONARY DISEASE 747 
Patients with AFEVi > 20% of baseline after 4 weeks did 
not differ from those with AFEVi I 20% in regard of 
smoking history (22 + 22 vs. 20 + 19 pack-years). 
Logistic regression was performed in order to estimate 
whether the levels of eosinophil markers were independent 
predictors of change of FEVi at the end of the study period. 
After adjustment for age, gender, pack-years, treatment 
and FEV, before treatment a significant positive correlation 
was found for S-ECP, S-EPO and B-Eos, but not for U- 
EPX. The odds ratio (95% CL) for an improvement of at 
least 20% in FEVr after 4 weeks with each increase of 
lOmgl-‘was 1.51 (1,03-2.20)forECPand 1.39(1.05-1.84) 
for EPO. The corresponding odds ratio for an increase of 
100 x lo6 1-l of B-Eos was 1.59 (1.09-2.31). 
Eleven patients relapsed during the first week and and 
received emergency treament, including steroids. During 
the last 3 weeks, another six patients relapsed. The 
significant differences and correlations which were found 
in the whole patient group still remained after excluding 
patients with relapses. No significant differences in inflam- 
matory markers were seen between patients who did or did 
not relapse. 
RELATION TO SMOKING HISTORY 
Seventeen patients had a smoking history of five pack-years 
or less (mean 0.7 yr) (non- or short-term smokers). None of 
them was a current smoker. Thirty-three patients had a 
smoking history of more than five pack-years (mean 30 yr) 
(long-term smokers) and six of them were current smokers. 
Women were over-represented in the non- or short-term 
smoking group (82%) and under-represented in the 
smoking group (42%) P < 0.01). Age did not differ between 
the groups (63 yr vs. 65 yr). 
The inflammatory markers before treatment in the two 
groups are shown in Table 2. The only significant difference 
was a higher S-MPO among long-term smokers compared 
with non- or short-term smokers (P-cO.05). Thirty-two 
patients were able to deliver a sputum sample sponta- 
neously. The rest of the patients delivered either insufficient 
amounts of sputum or just saliva. In sputum, the eosinophil 
markers were higher in the non- or short-term smoking 
group, but the difference did not reach statistical signifi- 
cance. 
The lung function, expressed as FEVt% predicted 
(FEV,%, pred) during the study period among non- or 
short-term smokers and long-term smokers is presented in 
Fig. 3. FEVi% pred was higher at all four time points in 
non- or short-term smokers compared with long-term 
smokers, but the change in lung function did not differ 
significantly between the groups. 
The eosinophil markers S-EPO, EPX in urine and B-eos 
before treatment were significantly correlated to the 
improvement in FEVi after 1 week (AFEVi as a percentage 
of baseline) in the non- or short-term smoking group (Table 
3, Fig. 4). The same was seen after 4 weeks, but the r-value 
for B-eos did not reach statistical significance. In sputum, a 
significant positive correlation was found between ECP and 
EPO and AFEV, after 1 and 4 weeks in the long-term group 
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TABLE 2. Inflammatory markers in blood, urine and sputum before treatment (means f SD) 
5 5 pack-years 25 pack-years P 
(n= 17) (n = 33) 
S-ECP @g l- ‘) 
S-EPO (pg 1-l) 
U-EPX/crea ((pg mmol-‘) 
B-eos (10 1-l) 
B-neutro (10 1-l) 
S-MPO (@g l- ‘) 
S-HNL ($g 1-l) 
Sputum ECP (mg 1-l) 
Sputum EPO (mg 1-l) 
Sputum IL-5 (ng 1-l) 
31k21 22+22 
41&38 36+39 
84+66 96f76 
503 + 377 4115290 
4.6k2.5 5.152.5 
631+389 879 f 546 * 
130+66 145+66 
66+ 106 20+26 
49+83 24+_48 
97k96 78+ 156 
*P < 0.05. S-ECP. Serum eosinophil cationic protein; S-EPO: serum eosinophil peroxidase; U-EPX urinary eosinophil protein 
X; S-MPO: serum myeloperoxidase, S-HNL: serum human neutrophil lipocaline. 
of smokers, but not in the non- or short-term smoking (r = -0.43, PcO.01) and after 4 weeks (r= -0.31, 
group (Table 3, Fig. 5). No correlation was found between ~~0.05). No relation was seen between pack-years and A 
the neutrophil markers and AFEVi in any group. FEVi or the inflammatory markers. 
If a group of heavy smokers with 2 20 pack-years is 
examined (n = 22), the positive correlation between AFEVi 
after 1 and 4 weeks and sputum ECP and EPO still remains, 
sputum ECP r=0.81, PcO.01, sputum EPO r=0.48, 
PcO.05 after 1 week, r = 0.55 respectively 0.68, P-co.05 
after 4 weeks. 
The levels of inflammatory markers in serum and sputum 
correlated significantly; ECP (r = 0.59, P < O.Ol), EPO 
(r =0.58, P<O.OOl). Sputum IL-5 showed a correlation to 
sputum ECP and EPO (r=0.73, P<O.OOl, r=0.46, 
PcO.01) and to S-ECP (r =0.48, P<O.Ol). 
Pack years were inversely related to FEVi (X pred) 
before treatment (r = -0.35, P<O.OS), after 1 week Discussion 
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FIG. 3. Change in lung function during the study period. 
(P-co.05 between non- or short-term smokers and 
long-term smokers). 
The main findings in this study were that the patients with 
higher levels of eosinophil markers before emergency 
treatment experienced a greater improvement in lung 
function, especially after 1 and 4 weeks. In non- or short- 
term smokers, this positive correlation was found in blood 
and urine, whereas in the long-term smokers it was seen 
in sputum. The absolute levels of inflammatory markers 
did not differ significantly between non- or short-term 
smokers and long-term smokers, except in the case of 
S-MPO. 
Previous studies which have investigated the relationship 
between the eosinophil inflammation and the effect of anti- 
inflammatory treatment in obstructive pulmonary disease 
have produced conflicting results. In a study (16) in which 
25 COPD patients were treated with prednisolone for 15 
days, responders (defined as AFEVi of at least 12% from 
baseline and at least 200 ml) had a larger number of 
eosinophils and a higher level of ECP in BAL fluid before 
treatment. In a recent study by Pizzichini et al. (17), sputum 
eosinophilia also predicts benefits from steroid treatment in 
COPD patients. In contrast, in a study by Keatings et al. 
(18), COPD patients were found to have increased levels of 
ECP and EPO in sputum before treatment, but did not 
respond by displaying either improved lung function or 
decreased levels of ECP and EPO following a 2-week course 
of budesonide or a 2-week course of prednisolone. In a 
study of asthmatics (12), current smokers were compared 
with non-smokers or ex-smokers. The smokers did not 
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TABLE 3. The correlation between eosinophil markers before treatment and the change in lung function after one and four 
weeks (r-values) 
AFEV, (% of baseline) 
After 1 week After 4 weeks 
4 5 pack-years > 5 pack-years < 5 pack-years > 5 pack-years 
S-ECP 04 0.07 0.51 0.31 
S-EPO 0.71** 0.34 0.64* 0.32 
U-EPX/crea 0.66* 0.09 0.55* 0.31 
B-eos 0.66* 0.18 0.51 0.15 
Sputum IL-5 0.13 0.28 0.12 0.43 
Sputum ECP 0.21 0.48* 0.071 0.77** 
Sputum EPO 0.40 0.67** 0.29 0.60* 
*p<@o5, **p= ~0.01. S-ECP: Serum eosinophil cationic protein; S-EPO: serum eosinophil peroxidase, U-EPX: urinary 
eosinophil protein X. 
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FIG. 4. The correlation between serum eosinophil 
peroxidase (S-EPO) and dFEVl after 1 week in non- or 
short-term smokers. Patients with lower levels of S-EPO 
showed less reversibility. 
improve in terms of FEVl or provocational concentration 
causing a 20% fall in FEV, (PC20) and the serum levels of 
ECP and EPX did not decrease during 1 yr of treatment 
with inhaled steroids. 
This study is close to the clinical situation, where it is 
often difficult to differentiate between asthma and COPD, 
especially during acute exacerbations. We have analysed 
our data with respect to smoking history, expressed as 
pack-years, with information that was obtained from the 
patients in an interview. In our study we used an arbitary 
rho = 0.77” 
0 “3,. , , , , , , , , , , , , , , , , , 
0 10 20 30 40 50 60 70 80 90 100 
Sputum JXP (mg’) before treatment 
FIG. 5. The correlation between sputum eosinophil 
cationic protein (ECP) and AFEV, after 4 weeks in long- 
term smokers. Patients with lower levels of sputum-ECP 
showed less reversibility. 
cut-off-point of 5 pack-years to divide never and short-term 
smokers from long-term smokers. No definite threshold 
exists concerning the magnitude of smoking and the risk of 
developing COPD. Mensinga et al., however, found that a 
smoking history of > 10 pack-years was associated with a 
significantly lower FEV, (19). We therefore chose a cut-off 
value of 5 pack-years in order to ensure that the patients in 
the short-term smoking group were purely asthmatics, 
while the long-term smoking group probably consists of 
both patients with asthma and patients with COPD. 
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The poor correlation between AFEVi and the eosinophil 
markers in sputum in the non- or short-term smoking 
group is therefore somewhat unexpected in the light of the 
well-established, causal role of eosinophils in asthma (2,20- 
23). This is even more surprising as a significant correlation 
was observed in the long-term and heavy smoking group. 
Our overall interpretation of this data is that eosinophil 
accumulation and activity are related to changes in lung 
function. It is therefore interesting that close correlations 
were found between IL-5 and these eosinophil markers in 
sputum,. These findings, could, however, have several 
explanations. One is that the Th2 cells produced and 
secreted IL-5 as part of the process of the attraction and 
activation of the eosinophils, a mechanism that is likely to 
be operative in asthma (24,25). Another possibility is that 
the correlation reflects the production and secretion of 
IL-5 by the accumulating eosinophils. The finding of 
correlations between the serum levels of eosinophil markers 
and lung function in the non- or short-term smoking group, 
but not in the heavy smoking group, may support this 
notion. Such correlations could indicate the systemic 
activation of eosinophils in the former group, as has been 
shown in asthmatics and the local activation of eosinophils 
in heavy smokers, i.e. in the COPD-like group. Our results 
therefore suggest different mechanisms for the attraction 
and activation of eosinophils in these two groups of 
patients. 
The best correlation between the eosinophil markers and 
the improvement in lung function is seen after 1 and 4 
weeks. This indicates that the significant association 
between the eosinophil markers and change in FEVi is 
mainly due to the steroids and not to the /32-agonists given 
in the acute phase. 
In this study, we measured various eosinophil markers in 
different body fluids. Eosinophil peroxidase (S-EPO) is a 
fairly new eosinophil marker. In one study, S-EPO was 
found to have a higher sensitivity to bronchial hyper- 
responsiveness than S-ECP and B-Eos (26). In our study, S- 
EPO had a better correlation to AFEVi than S-ECP, but no 
major differences were seen in sputum. Measurements of 
eosinophil markers in urine are currently of interest 
following the recent finding of high levels of EPX in the 
urine of asthmatic children (27,28). Urine EPX appears to 
correlate with lung function and asthma symptoms, as it 
did in our study, Furthermore, correlations were also seen 
between changes in urine EPX and changes in lung function 
after treatment with inhaled steroids in these studies. 
Owing to the risk of bronchospasm, (29) and because this 
was a study of patients with acute exacerbations, we did not 
use the induced sputum method. Good agreement between 
measurements of induced and spontaneous sputum has 
been found (30). Various methods for sputum preparation 
have been used for the measurement of fluid phase markers. 
The most common method includes treating sputum with 
reducing agents such as dithiothreitol (DTT) and measur- 
ing markers in cell free supernatant (31,32). Other 
approaches include measurement of markers in cell-free 
supernatant after treatment by ultrasonication (33) or in 
samples after treatment with DTT and the extraction of the 
intracellular total markers content (34). The present study 
includes ultrasonication and the measurement of total 
content of markers, which includes extracellular and 
intracellular extracted markers. One advantage of using 
this method is the reduced risk of protein destruction due to 
the presence of reducing agents, and another is the simpler 
sample handling procedure. 
We conclude that patients with obstructive pulmonary 
disease with acute exacerbations and high levels of 
eosinophil markers respond better to treatment. Our results 
also indicate that, in patients with COPD, analyses of 
sputum may provide an indication of whether a patient will 
or will not respond favourably to steroid treatment. 
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